Ultrasensitive Plasma p-Tau217 Assays Revolutionize Early Asymptomatic Alzheimer's Diagnosis

Byline: Dr. Rachel Aris, Chief Scientific Editor • November 6, 2026 • 5 min read

The diagnosis of preclinical Alzheimer's disease has taken an enormous leap forward with the commercial validation of automated blood plasma assays measuring phosphorylated tau at threonine 217 (p-tau217).

Replacing Invasive Spinal Taps and Costly PET Scans

Historically, determining whether mild cognitive symptoms were driven by Alzheimer's pathology required either an invasive cerebrospinal fluid lumbar puncture or an expensive radioactive Amyloid-PET scan costing upwards of $4,500.

The new electrochemiluminescence assays detect sub-picogram concentrations of circulating p-tau217 in ordinary venous blood, demonstrating an area under the ROC curve (AUC) of 0.96 when benchmarked against post-mortem neuropathological confirmation.

← Back to Front Page

Published under the HUTXJ Health & Science Charter